Coloplast Company Insiders
| CLPBY Stock | USD 12.58 0.07 0.56% |
Coloplast employs about 14.5 K people. The company is managed by 10 executives with a total tenure of roughly 49 years, averaging almost 4.0 years of service per executive, having 1450.0 employees per reported executive. Break down of Coloplast's management performance can provide insight into the company performance.
| Alain Morvan President Senior Vice President Sales Europe |
| Nicolai Andersen President Senior Vice President Wound Care |
Coloplast |
Coloplast's latest congressional trading
Congressional trading in companies like Coloplast A, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Coloplast by those in governmental positions are based on the same information available to the general public.
| 2024-06-08 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Coloplast Management Team Effectiveness
The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast's management efficiency ratios could be used to measure how well Coloplast manages its routine affairs as well as how well it operates its assets and liabilities.Coloplast Workforce Comparison
Coloplast A is rated below average in number of employees category among its peers. The total workforce of Medical Instruments & Supplies industry is currently estimated at about 482,809. Coloplast holds roughly 14,500 in number of employees claiming about 3.0% of all equities under Medical Instruments & Supplies industry.
The company has Profit Margin (PM) of 0.2 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.3 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.3. Coloplast A Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Coloplast A Price Series Summation is a cross summation of Coloplast price series and its benchmark/peer.
Coloplast Notable Stakeholders
A Coloplast stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Coloplast often face trade-offs trying to please all of them. Coloplast's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Coloplast's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Alain Morvan | Senior Vice President Sales Europe | Profile | |
| Nicolai Andersen | Senior Vice President Wound Care | Profile | |
| Anders LonningSkovgaard | CFO, Executive Vice President Member of the Executive Management | Profile | |
| Paul Marcun | Senior Vice President Emerging Markets | Profile | |
| Allan Rasmussen | Executive VP of Global Operations | Profile | |
| Kristian Villumsen | Executive VP of Chronic Care | Profile | |
| Thomas Barfod | Director, Employee Representative | Profile | |
| Ellen Bjurgert | VP Relations | Profile | |
| Dorthe Ronnau | VP Culture | Profile | |
| Dennis Kaysen | Director Communications | Profile |
About Coloplast Management Performance
The success or failure of an entity such as Coloplast A often depends on how effective the management is. Coloplast management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Coloplast management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Coloplast management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast is traded on OTC Exchange in the United States.
Please note, the imprecision that can be found in Coloplast's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Coloplast A. Check Coloplast's Beneish M Score to see the likelihood of Coloplast's management manipulating its earnings.
Coloplast Workforce Analysis
Traditionally, organizations such as Coloplast use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Coloplast within its industry.Coloplast Manpower Efficiency
Return on Coloplast Manpower
| Revenue Per Employee | 1.6M | |
| Revenue Per Executive | 2.3B | |
| Net Income Per Employee | 324.6K | |
| Net Income Per Executive | 470.6M |
Additional Tools for Coloplast Pink Sheet Analysis
When running Coloplast's price analysis, check to measure Coloplast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coloplast is operating at the current time. Most of Coloplast's value examination focuses on studying past and present price action to predict the probability of Coloplast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coloplast's price. Additionally, you may evaluate how the addition of Coloplast to your portfolios can decrease your overall portfolio volatility.